Rigel Pharmaceuticals宣布,其Gavreto®(普拉塞替尼)用于治疗RET融合阳性非小细胞肺癌(RET+ NSCLC)患者的ARROW临床试验最终数据,已在权威期刊《临床肿瘤学杂志》(Journal of Clinical Oncology)上正式发表。该数据的公布标志着这一靶向疗法在临床研究领域的重要里程碑。
Rigel Pharmaceuticals宣布,其Gavreto®(普拉塞替尼)用于治疗RET融合阳性非小细胞肺癌(RET+ NSCLC)患者的ARROW临床试验最终数据,已在权威期刊《临床肿瘤学杂志》(Journal of Clinical Oncology)上正式发表。该数据的公布标志着这一靶向疗法在临床研究领域的重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.